Publications by authors named "Marie Francillard"
Article Synopsis
- Dyspnea is a common and significant symptom that greatly impacts the quality of life for terminally ill patients, with a recorded incidence of 13,282 episodes during 2,608 hospital stays in a palliative care setting.
- Dyspnea appears more frequently in patients with cancer, especially those with pulmonary metastasis, and its occurrence varies widely based on the type of primary cancer, with rates ranging from 24% to 60%.
- There's a notable percentage of cancer patients who experience dyspnea exclusively in the last days of their life, highlighting the need for careful assessment and treatment strategies that differentiate between terminal and earlier episodes of dyspnea.
Objective: The aim of this study was to demonstrate the superiority of benfluorex over placebo as an add-on therapy in type 2 diabetic patients in whom diabetes is insufficiently controlled by sulfonylurea monotherapy and who have a limitation for the use of metformin.
Research Design And Methods: Type 2 diabetic patients with HbA(1c) (A1C) (7-10%) who were receiving the maximum tolerated sulfonylurea dose and had a contraindication to or poor tolerance of metformin were randomly assigned (double blind) to receive benfluorex 450 mg/day (n = 165) or placebo (n = 160) for 18 weeks. The main efficacy criterion was A1C, analyzed as the change from baseline to the end of treatment using ANCOVA with baseline and country as covariates.